Objectives: This randomized, double‐blind, placebo‐controlled study (NCT04557085), conducted in China, Japan, and the Republic of Korea, evaluated the efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures. Methods: Adults 18–70 years of age with ≥8 seizures (focal aware motor, focal impaired awareness, or focal to bilateral tonic–clonic) during an 8‐week baseline, despite treatment with 1–3 antiseizure medications (ASMs), were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg/day. The study included an 18‐week titration phase and a 6‐week maintenance phase. The primary efficacy analysis was a hierarchical step‐down comparison of the percent change from baseline in 28‐day seizure frequency vs placebo during the maintenance phase for cenobamate 200, then 400, and then 100 mg/day. Results: Among 519 patients randomized, 446 received ≥1 dose of study drug and had ≥1 efficacy measure during the maintenance phase (placebo, n = 117; 100 mg/day, n = 113; 200 mg/day, n = 113; and 400 mg/day, n = 103). Median percent change in seizure frequency during the maintenance phase was −25.9% for placebo vs −42.6%, −78.3%, and −100% for cenobamate 100, 200, and 400 mg/day, respectively (all p 's < .001). During the 12‐week period encompassing the last 6 weeks of titration and the 6‐week maintenance phase (secondary outcome), the median percent change in seizure frequency was −20.1% for placebo vs −42.6%, −77.1%, and −89.2% for cenobamate 100, 200, and 400 mg/day, respectively. Seizure‐free rates during the maintenance phase were 2.6% of patients for placebo vs 12.4%, 30.1%, and 52.4% for cenobamate 100, 200, and 400 mg/day, respectively, and during the 12‐week period were 0.8% for placebo vs 8.5%, 19.7%, and 30.6% for the cenobamate groups. The most common treatment‐emergent adverse events in cenobamate patients (≥20%) were dose‐related dizziness and somnolence. Significance: Cenobamate 100, 200, and 400 mg/day reduced focal seizures in Asian patients in a dose‐related fashion and was generally well tolerated.